REPONEX PHARMACEUTICALS A/S: Financial statements 2012
CVR: 30082346
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
REPONEX PHARMACEUTICALS A/S (CVR 30082346) has filed annual accounts for 2012. In 2012, the company reported a net result of DKK -17,837. Equity in the 2012 report amounted to DKK 79,749. The solvency ratio was 8.5%.
- Profit/Loss
- DKK -17,837
- Equity
- DKK 79,749
- Total Assets
- DKK 940,203
Official annual report
Keep an eye on REPONEX PHARMACEUTICALS A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of February 15, 2012, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of REPONEX PHARMACEUTICALS A/S.
As of February 15, 2012, DKNF 387 ApS has stepped down as auditor of REPONEX PHARMACEUTICALS A/S.
About REPONEX PHARMACEUTICALS A/S
REPONEX PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named REPONEX PHARMACEUTICALS ApS and TRIFOILIUM ApS. The management consists of Christian Henrik Tange. The board consists of Christian Vinding Thomsen (chair), Troels Peter Troelsen and Charlotte Pahl. The company is owned by Pharma Equity Group A/S. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000.